These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25600955)

  • 41. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insight in inpatients with schizophrenia: relationship to symptoms and neuropsychological functioning.
    Zhou Y; Rosenheck R; Mohamed S; Zhang J; Chang Q; Ou Y; Sun B; Ning Y; He H
    Schizophr Res; 2015 Feb; 161(2-3):376-81. PubMed ID: 25533592
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reasons for adherence and nonadherence: a pilot study comparing first- and multi-episode schizophrenia patients.
    Sapra M; Weiden PJ; Schooler NR; Sunakawa-McMillan A; Uzenoff S; Burkholder P
    Clin Schizophr Relat Psychoses; 2014 Jan; 7(4):199-206. PubMed ID: 23428784
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Why do patients with schizophrenia who have poor insight still take antipsychotics? Memory deficits as moderators between adherence belief and behavior.
    Staring AB; van der Gaag M; Duivenvoorden HJ; Weiden PJ; Mulder CL
    J Psychiatr Pract; 2011 Sep; 17(5):320-9. PubMed ID: 21926527
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Psychiatrists' awareness of partial- and non-adherence to antipsychotic medication in schizophrenia: results from the Australian ADHES survey.
    Kulkarni J; Reeve-Parker K
    Australas Psychiatry; 2015 Jun; 23(3):258-64. PubMed ID: 25783668
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia.
    Dibonaventura M; Gabriel S; Dupclay L; Gupta S; Kim E
    BMC Psychiatry; 2012 Mar; 12():20. PubMed ID: 22433036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictors of medication non-adherence in Bulgarian outpatients with schizophrenia.
    Vassileva I; Milanova V; Asan T
    Community Ment Health J; 2014 Oct; 50(7):854-61. PubMed ID: 24452824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Subjective reasons for adherence to psychotropic medication and associated factors among older adults with schizophrenia.
    Sapra M; Vahia IV; Reyes PN; Ramirez P; Cohen CI
    Schizophr Res; 2008 Dec; 106(2-3):348-55. PubMed ID: 18851906
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simplifying adherence in schizophrenia.
    Hardeman SM; Harding RK; Narasimhan M
    Psychiatr Serv; 2010 Apr; 61(4):405-8. PubMed ID: 20360281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia.
    Rocca P; Crivelli B; Marino F; Mongini T; Portaleone F; Bogetto F
    Compr Psychiatry; 2008; 49(2):170-6. PubMed ID: 18243890
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A peer support programme for enhancing adherence to oral antipsychotic medication in consumers with schizophrenia.
    Boardman G; McCann T; Kerr D
    J Adv Nurs; 2014 Oct; 70(10):2293-302. PubMed ID: 24628395
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The mediating effect of family function and medication adherence between symptoms and mental disability among Chinese patients with schizophrenia: a cross-sectional study.
    Sun Y; Wang M; Zhou Y; Wang L; Zhang H; Lv Y; Li G
    Psychol Health Med; 2019 Jun; 24(5):559-569. PubMed ID: 30332286
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonadherence to antipsychotics: the role of positive attitudes towards positive symptoms.
    Moritz S; Hünsche A; Lincoln TM
    Eur Neuropsychopharmacol; 2014 Nov; 24(11):1745-52. PubMed ID: 25444234
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medication adherence and subjective weight perception in patients with first-episode psychotic disorder.
    Wong MM; Chen EY; Lui SS; Tso S
    Clin Schizophr Relat Psychoses; 2011 Oct; 5(3):135-41. PubMed ID: 21983497
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects.
    Kao YC; Liu YP
    Compr Psychiatry; 2010; 51(6):557-65. PubMed ID: 20965300
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improving treatment adherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2011 Sep; 72(9):e28. PubMed ID: 21951990
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medication adherence in schizophrenia: a comparison between outpatients and relapse cases.
    Razali SM; Yusoff MZ
    East Asian Arch Psychiatry; 2014 Jun; 24(2):68-74. PubMed ID: 24986201
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of insights on medication adherence in patients with schizophrenia.
    Kalkan E; Kavak Budak F
    Perspect Psychiatr Care; 2020 Jan; 56(1):222-228. PubMed ID: 31215655
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment adherence in schizophrenia and schizoaffective disorder.
    Goff DC; Hill M; Freudenreich O
    J Clin Psychiatry; 2011 Apr; 72(4):e13. PubMed ID: 21527119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.